Change in antimicrobial resistance rates in Pseudomonas aeruginosa isolates by years: Analysis for seven years

Basit Öğe Kaydı
dc.contributor.authorMansur, Ahmet
dc.contributor.authorGündüz, Ayten
dc.date.accessioned2025-10-24T18:06:51Z
dc.date.available2025-10-24T18:06:51Z
dc.date.issued2025
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective: Pseudomonas aeruginosa is naturally resistant to many antimicrobial drugs, and resistance rates against currently available antimicrobials may vary according to different geographical regions, hospitals and years. The ability to develop resistance to antimicrobials during the treatment of infections causes treatment difficulties and requires constant monitoring of the resistance profile. This study aimed to retrospectively determine the resistance rates of P. aeruginosa strains isolated from different culture samples sent to the microbiology laboratory from hospitalized patients to various antimicrobials and to examine their changes over the years. Methods: 1746 P. aeruginosa isolates grown in inpatient culture samples sent to the microbiology laboratory from all clinics between January 2016 and December 2022 were evaluated retrospectively. Vitek 2 Compact automated system (BioMérieux, France) was used for antimicrobial susceptibility testing (AST). AST results were evaluated according to Minimum Inhibitory Concentration (MIC) values according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. EUCAST and Clinical and Laboratory Standards Institute (CLSI) guidelines only approve the broth microdilution method for colistin resistance, so colistin resistance rates were not included in our study. Results: P. aeruginosa strains were isolated most frequently from respiratory tract samples (57.2%) and urine samples (24.5%), and most frequently from samples sent from Intensive Care Units (ICU) (60.4%). The lowest antimicrobial resistance rates for all strains isolated in seven years were amikacin (16.3%) and ceftazidime (22.3%), while meropenem resistance was 33.6% and imipenem resistance was 44.3%. Ciprofloxacin (47.9%) and piperacillin-tazobactam (51.1%) were found to be the antimicrobials with the highest resistance rates. Resistance rates for all other antimicrobials, except amikacin and aztreonam, increased significantly from 2016 to 2022 (p<0,001- p:0,002). Conclusion: In our study, amikacin and ceftazidime were determined to be the most effective antibiotics for P. aeruginosa strains, and there are increasing resistance rates against antimicrobials over the years. Continuous monitoring of antimicrobial resistance rates for each hospital will contribute to the determination of empirical treatment options and appropriate treatment approaches. © 2025 Elsevier B.V., All rights reserved.
dc.identifier.doi10.5505/TurkHijyen.2025.18828
dc.identifier.endpage400
dc.identifier.issn0377-9777
dc.identifier.issue3
dc.identifier.scopus2-s2.0-105017917622
dc.identifier.scopusqualityQ4
dc.identifier.startpage393
dc.identifier.urihttps://doi.rog/10.5505/TurkHijyen.2025.18828
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3222
dc.identifier.volume82
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherRefik Saydam National Public Health Agency (RSNPHA)
dc.relation.ispartofTurk Hijyen ve Deneysel Biyoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzScopus_20251023
dc.subjectAntimicrobial resistance
dc.subjectEUCAST
dc.subjectPseudomonas aeruginosa
dc.titleChange in antimicrobial resistance rates in Pseudomonas aeruginosa isolates by years: Analysis for seven years
dc.title.alternativePseudomonas aeruginosa izolatlarında antimikrobiyal direnç oranlarının yıllara göre değişimi: 7 yıllık analiz
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu